This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Ultragenyx Pharmaceutical, Inc. (RARE) declines this week from a C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RARE stock.

Agios Pharmaceuticals, Inc. (AGIO) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

This is a rough week for Eagle Pharmaceuticals, Inc. (EGRX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in sales growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

Radius Health Inc (RDUS) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of RDUS stock.

This week, Acorda Therapeutics, Inc. (ACOR) drops from a C to a D rating. Acorda Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

La Jolla Pharmaceutical Company (LJPC) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Cellular Biomedicine Group, Inc.’s (CBMG) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of CBMG stock.

Recro Pharma, Inc.’s (REPH) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of REPH stock.

Slipping from a C to a D rating, Stemline Therapeutics, Inc. (STML) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of STML stock.

TG Therapeutics, Inc. (TGTX) slips from a D to a F this week. TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TGTX stock.

ZIOPHARM Oncology, Inc. (ZIOP) earns a D this week, moving down from last week’s grade of C. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

This week, Mirati Therapeutics Inc. (MRTX) drops from a D to a F rating. Mirati Therapeutics Inc. engages in the development of therapeutics for the treatment of cancer. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

Slipping from a C to a D rating, Vascular Biogenics Ltd. (VBLT) takes a hit this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VBLT stock.

CareDx, Inc. (CDNA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

VistaGen Therapeutics, Inc.’s (VTGN) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of VTGN stock.

This week, Synergy Pharmaceuticals, Inc.’s (SGYP) rating worsens to a D from the company’s C rating a week ago. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Calithera Biosciences, Inc. (CALA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CALA stock.

Regulus Therapeutics Inc. (RGLS) declines this week from a D to a F. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

ARCA biopharma, Inc. (ABIO) gets weaker ratings this week as last week’s D drops to a F. ARCA biopharma, Inc. is a biopharmaceutical company whose main focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ABIO stock.

BioCryst Pharmaceuticals, Inc. (BCRX) earns a F this week, moving down from last week’s grade of D. BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. The company also gets F’s in sales growth, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BCRX stock.

ContraFect Corp. (CFRX) slips from a C to a D this week. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

This is a rough week for Arena Pharmaceuticals, Inc. (ARNA). The company’s rating falls to F from the previous week’s D. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARNA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.